The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome
Φόρτωση...
Ημερομηνία
Συγγραφείς
Filippatos, T. D.
Liberopoulos, E. N.
Kostapanos, M.
Gazi, I. F.
Papavasiliou, E. C.
Kiortsis, D. N.
Tselepis, A. D.
Elisaf, M. S.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Diabetes Obesity & Metabolism
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
Objective: We assessed the effect of orlistat and fenofibrate, alone or in combination, on plasma high-density lipoprotein (HDL) subfractions and plasma pre-beta1-HDL levels in overweight and obese subjects with metabolic syndrome (MetS). Methods: Patients (n = 89) were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg three times daily (O group), micronized fenofibrate 200 mg/day (F group) or both (OF group) for 6 months. HDL subfractions were determined using a polyacrylamide gel tube electrophoresis method and pre-beta1-HDL levels using enzyme-linked immunoabsorbent assay. Results: We observed a significant change of high-density lipoprotein cholesterol (HDL-C) levels only in the F group (+3%, p < 0.05). Large HDL-C levels were significantly increased and small HDL-C levels were significantly reduced with O administration. In F group we observed a significant increase of small HDL-C levels. No significant change of large or small HDL-C levels was observed with combination treatment. We observed a significant increase of pre-beta1-HDL levels in all groups, which was significantly greater in OF group compared with O or F monotherapy. Conclusion: OF combination increased the antiatherogenic pre-beta1-HDL levels in overweight and obese patients with MetS. Furthermore, OF combination counterbalanced the reduction of small HDL-C levels observed with orlistat monotherapy.
Περιγραφή
Λέξεις-κλειδιά
fenofibrate, hdl subfractions, metabolic syndrome, orlistat, pre-beta1-hdl, sandwich enzyme-immunoassay, low-fat diet, intervention trial, cholesterol efflux, diabetic-patients, hepatic lipase, hdl, pre-beta-1-hdl, subclasses, insulin
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
<Go to ISI>://000255602500005
http://onlinelibrary.wiley.com/store/10.1111/j.1463-1326.2007.00733.x/asset/j.1463-1326.2007.00733.x.pdf?v=1&t=h0f7uumw&s=99a398f9b534f6360017792a0a3169303b484abd
http://onlinelibrary.wiley.com/store/10.1111/j.1463-1326.2007.00733.x/asset/j.1463-1326.2007.00733.x.pdf?v=1&t=h0f7uumw&s=99a398f9b534f6360017792a0a3169303b484abd
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας